Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 362

1.

The influence of single-nucleotide polymorphisms on overall survival and toxicity in cabazitaxel-treated patients with metastatic castration-resistant prostate cancer.

Belderbos BPS, de With M, Singh RK, Agema BC, El Bouazzaoui S, Oomen-de Hoop E, de Wit R, van Schaik RHN, Mathijssen RHJ, Bins S.

Cancer Chemother Pharmacol. 2020 Jan 1. doi: 10.1007/s00280-019-04011-0. [Epub ahead of print]

PMID:
31893292
2.

Health-related Quality of Life and Pain in a Real-world Castration-resistant Prostate Cancer Population: Results From the PRO-CAPRI Study in the Netherlands.

Kuppen MCP, Westgeest HM, van den Eertwegh AJM, Coenen JLLM, van Moorselaar RJA, van den Berg P, Geenen MM, Mehra N, Hendriks MP, Lampe MI, van de Luijtgaarden ACM, Peters FPJ, Roeleveld TA, Smilde TJ, de Wit R, van Oort IM, Gerritsen WR, Uyl-de Groot CA.

Clin Genitourin Cancer. 2019 Dec 5. pii: S1558-7673(19)30366-0. doi: 10.1016/j.clgc.2019.11.015. [Epub ahead of print]

PMID:
31883940
3.

Impact of progression at baseline and on-treatment progression events in three large prostate cancer trials.

Robbrecht DG, Delanoy N, Tannock IF, Tombal B, Eisenberger M, Fizazi K, Sartor O, Mercier F, Oudard S, de Wit R.

Eur J Cancer. 2020 Jan;125:142-152. doi: 10.1016/j.ejca.2019.10.029. Epub 2019 Dec 11.

4.

Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study.

Antonarakis ES, Piulats JM, Gross-Goupil M, Goh J, Ojamaa K, Hoimes CJ, Vaishampayan U, Berger R, Sezer A, Alanko T, de Wit R, Li C, Omlin A, Procopio G, Fukasawa S, Tabata KI, Park SH, Feyerabend S, Drake CG, Wu H, Qiu P, Kim J, Poehlein C, de Bono JS.

J Clin Oncol. 2019 Nov 27:JCO1901638. doi: 10.1200/JCO.19.01638. [Epub ahead of print]

PMID:
31774688
5.

Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial.

Petrylak DP, de Wit R, Chi KN, Drakaki A, Sternberg CN, Nishiyama H, Castellano D, Hussain SA, Fléchon A, Bamias A, Yu EY, van der Heijden MS, Matsubara N, Alekseev B, Necchi A, Géczi L, Ou YC, Coskun HS, Su WP, Bedke J, Gakis G, Percent IJ, Lee JL, Tucci M, Semenov A, Laestadius F, Peer A, Tortora G, Safina S, Garcia Del Muro X, Rodriguez-Vida A, Cicin I, Harputluoglu H, Tagawa ST, Vaishampayan U, Aragon-Ching JB, Hamid O, Liepa AM, Wijayawardana S, Russo F, Walgren RA, Zimmermann AH, Hozak RR, Bell-McGuinn KM, Powles T; RANGE study investigators.

Lancet Oncol. 2020 Jan;21(1):105-120. doi: 10.1016/S1470-2045(19)30668-0. Epub 2019 Nov 18.

PMID:
31753727
6.

The genomic landscape of metastatic castration-resistant prostate cancers reveals multiple distinct genotypes with potential clinical impact.

van Dessel LF, van Riet J, Smits M, Zhu Y, Hamberg P, van der Heijden MS, Bergman AM, van Oort IM, de Wit R, Voest EE, Steeghs N, Yamaguchi TN, Livingstone J, Boutros PC, Martens JWM, Sleijfer S, Cuppen E, Zwart W, van de Werken HJG, Mehra N, Lolkema MP.

Nat Commun. 2019 Nov 20;10(1):5251. doi: 10.1038/s41467-019-13084-7.

7.

Platinum exposure and cause-specific mortality among patients with testicular cancer.

Groot HJ, van Leeuwen FE, Lubberts S, Horenblas S, de Wit R, Witjes JA, Groenewegen G, Poortmans PM, Hulshof MCCM, Meijer OWM, de Jong IJ, van den Berg HA, Smilde TJ, Vanneste BGL, Aarts MJB, Jóźwiak K, van den Belt-Dusebout AW, Gietema JA, Schaapveld M.

Cancer. 2020 Feb 1;126(3):628-639. doi: 10.1002/cncr.32538. Epub 2019 Nov 15.

PMID:
31730712
8.

Real-world Outcomes of Sequential Androgen-receptor Targeting Therapies with or Without Interposed Life-prolonging Drugs in Metastatic Castration-resistant Prostate Cancer: Results from the Dutch Castration-resistant Prostate Cancer Registry.

Kuppen MCP, Westgeest HM, van den Eertwegh AJM, van Moorselaar RJA, van Oort IM, Coenen JLLM, van den Bergh ACMF, Mehra N, Somford DM, Bergman AM, Ten Bokkel Huinink D, Fossion L, Geenen MM, Hendriks MP, van de Luijtgaarden ACM, Polee MB, Weijl NI, van de Wouw AJ, de Wit R, Uyl-de Groot CA, Gerritsen WR.

Eur Urol Oncol. 2019 Oct 7. pii: S2588-9311(19)30146-4. doi: 10.1016/j.euo.2019.09.005. [Epub ahead of print]

PMID:
31601523
9.

Refinement of the Management of Germ Cell Cancer: What's Next?

de Wit R.

J Clin Oncol. 2019 Nov 20;37(33):3063-3065. doi: 10.1200/JCO.19.02302. Epub 2019 Oct 4. No abstract available.

PMID:
31584840
10.

Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer.

de Wit R, de Bono J, Sternberg CN, Fizazi K, Tombal B, Wülfing C, Kramer G, Eymard JC, Bamias A, Carles J, Iacovelli R, Melichar B, Sverrisdóttir Á, Theodore C, Feyerabend S, Helissey C, Ozatilgan A, Geffriaud-Ricouard C, Castellano D; CARD Investigators.

N Engl J Med. 2019 Dec 26;381(26):2506-2518. doi: 10.1056/NEJMoa1911206. Epub 2019 Sep 30.

PMID:
31566937
11.

Associations between AR-V7 status in circulating tumour cells, circulating tumour cell count and survival in men with metastatic castration-resistant prostate cancer.

Belderbos BPS, Sieuwerts AM, Hoop EO, Mostert B, Kraan J, Hamberg P, Van MN, Beaufort CM, Onstenk W, van Soest RJ, Martens J, Sleijfer S, de Wit R, Mathijssen RHJ, Lolkema MP.

Eur J Cancer. 2019 Nov;121:48-54. doi: 10.1016/j.ejca.2019.08.005. Epub 2019 Sep 19.

PMID:
31542641
12.

Second-Line Cabazitaxel Treatment in Castration-Resistant Prostate Cancer Clinical Trials Compared to Standard of Care in CAPRI: Observational Study in the Netherlands.

Westgeest HM, Kuppen MCP, van den Eertwegh AJM, de Wit R, Coenen JLLM, van den Berg HPP, Mehra N, van Oort IM, Fossion LMCL, Hendriks MP, Bloemendal HJ, van de Luijtgaarden ACM, Ten Bokkel Huinink D, van den Bergh ACMF, van den Bosch J, Polee MB, Weijl N, Bergman AM, Uyl-de Groot CA, Gerritsen WR.

Clin Genitourin Cancer. 2019 Oct;17(5):e946-e956. doi: 10.1016/j.clgc.2019.05.018. Epub 2019 May 31.

PMID:
31439536
13.

Circulating Tumor Cell Enumeration and Characterization in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Cabazitaxel.

de Kruijff IE, Sieuwerts AM, Onstenk W, Kraan J, Smid M, Van MN, van der Vlugt-Daane M, Hoop EO, Mathijssen RHJ, Lolkema MP, de Wit R, Hamberg P, Meulenbeld HJ, Beeker A, Creemers GJ, Martens JWM, Sleijfer S.

Cancers (Basel). 2019 Aug 20;11(8). pii: E1212. doi: 10.3390/cancers11081212.

14.

Cost-effectiveness of Pembrolizumab for Patients with Advanced, Unresectable, or Metastatic Urothelial Cancer Ineligible for Cisplatin-based Therapy.

Patterson K, Prabhu V, Xu R, Li H, Meng Y, Zarabi N, Zhong Y, Batteson R, Pellissier J, Keefe S, Grivas P, de Wit R.

Eur Urol Oncol. 2019 Sep;2(5):565-571. doi: 10.1016/j.euo.2018.09.009. Epub 2018 Nov 8.

15.

Cost-effectiveness of Pembrolizumab as Second-line Therapy for the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma in Sweden.

Srivastava T, Prabhu VS, Li H, Xu R, Zarabi N, Zhong Y, Pellissier JM, Perini RF, de Wit R, Mamtani R.

Eur Urol Oncol. 2018 Nov 20. pii: S2588-9311(18)30172-X. doi: 10.1016/j.euo.2018.09.012. [Epub ahead of print]

16.

Fine-tuning of seasonal timing of breeding is regulated downstream in the underlying neuro-endocrine system in a small songbird.

Verhagen I, Laine VN, Mateman AC, Pijl A, de Wit R, van Lith B, Kamphuis W, Viitaniemi HM, Williams TD, Caro SP, Meddle SL, Gienapp P, van Oers K, Visser ME.

J Exp Biol. 2019 Sep 3;222(Pt 17). pii: jeb202481. doi: 10.1242/jeb.202481.

PMID:
31371403
17.

Novel treatment options in the management of metastatic castration-naïve prostate cancer; which treatment modality to choose?

Belderbos BPS, de Wit R, Lolkema MPJ, Mathijssen RHJ, van Soest RJ.

Ann Oncol. 2019 Oct 1;30(10):1591-1600. doi: 10.1093/annonc/mdz210.

PMID:
31340031
18.

AR splice variants in circulating tumor cells of patients with castration-resistant prostate cancer: relation with outcome to cabazitaxel.

Sieuwerts AM, Onstenk W, Kraan J, Beaufort CM, Van M, De Laere B, Dirix LY, Hamberg P, Beeker A, Meulenbeld HJ, Creemers GJ, van Weerden WM, Jenster GW, Nieuweboer AJM, Mathijssen RHJ, de Wit R, Martens JWM, Sleijfer S.

Mol Oncol. 2019 Aug;13(8):1795-1807. doi: 10.1002/1878-0261.12529. Epub 2019 Jun 28.

19.

Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up.

Fradet Y, Bellmunt J, Vaughn DJ, Lee JL, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK, Necchi A, Gerritsen W, Gurney H, Quinn DI, Culine S, Sternberg CN, Nam K, Frenkl TL, Perini RF, de Wit R, Bajorin DF.

Ann Oncol. 2019 Jun 1;30(6):970-976. doi: 10.1093/annonc/mdz127.

20.

A bypass mechanism of abiraterone-resistant prostate cancer: Accumulating CYP17A1 substrates activate androgen receptor signaling.

Moll JM, Kumagai J, van Royen ME, Teubel WJ, van Soest RJ, French PJ, Homma Y, Jenster G, de Wit R, van Weerden WM.

Prostate. 2019 Jun;79(9):937-948. doi: 10.1002/pros.23799. Epub 2019 Apr 24.

21.

Effects of prednisone on docetaxel pharmacokinetics in men with metastatic prostate cancer: A randomized drug-drug interaction study.

Belderbos BPS, Hussaarts KGAM, van Harten LJ, Oomen-de Hoop E, de Bruijn P, Hamberg P, van Alphen RJ, Haberkorn BCM, Lolkema MP, de Wit R, van Soest RJ, Mathijssen RHJ.

Br J Clin Pharmacol. 2019 May;85(5):986-992. doi: 10.1111/bcp.13889. Epub 2019 Mar 21.

PMID:
30737835
22.

Reply to Thomas Gevaert, Markus Eckstein, Rodolfo Montironi, and Antonio Lopez-Beltran's Letter to the Editor re: Maud Rijnders, Astrid A.M. van der Veldt, Tahlita C.M. Zuiverloon, et al. PD-L1 Antibody Comparison in Urothelial Carcinoma. Eur Urol 2019;75:538-40.

Rijnders M, van der Veldt AAM, de Wit R, van Leenders GJLH.

Eur Urol. 2019 Jun;75(6):e160-e161. doi: 10.1016/j.eururo.2019.01.039. Epub 2019 Feb 2. No abstract available.

PMID:
30723047
23.

PD-L1 Antibody Comparison in Urothelial Carcinoma.

Rijnders M, van der Veldt AAM, Zuiverloon TCM, Grünberg K, Thunnissen E, de Wit R, van Leenders GJLH.

Eur Urol. 2019 Mar;75(3):538-540. doi: 10.1016/j.eururo.2018.11.002. Epub 2018 Nov 27. No abstract available.

PMID:
30497882
24.

Superiority of Step-up Approach vs Open Necrosectomy in Long-term Follow-up of Patients With Necrotizing Pancreatitis.

Hollemans RA, Bakker OJ, Boermeester MA, Bollen TL, Bosscha K, Bruno MJ, Buskens E, Dejong CH, van Duijvendijk P, van Eijck CH, Fockens P, van Goor H, van Grevenstein WM, van der Harst E, Heisterkamp J, Hesselink EJ, Hofker S, Houdijk AP, Karsten T, Kruyt PM, van Laarhoven CJ, Laméris JS, van Leeuwen MS, Manusama ER, Molenaar IQ, Nieuwenhuijs VB, van Ramshorst B, Roos D, Rosman C, Schaapherder AF, van der Schelling GP, Timmer R, Verdonk RC, de Wit RJ, Gooszen HG, Besselink MG, van Santvoort HC; Dutch Pancreatitis Study Group.

Gastroenterology. 2019 Mar;156(4):1016-1026. doi: 10.1053/j.gastro.2018.10.045. Epub 2018 Nov 2.

PMID:
30391468
25.

Risk of diabetes after para-aortic radiation for testicular cancer.

Groot HJ, Gietema JA, Aleman BMP, Incrocci L, de Wit R, Witjes JA, Groenewegen G, de Brouwer P, Meijer OWM, Hulshof MCCM, van den Berg HA, Smilde TJ, Vanneste BGL, Aarts MJ, van den Bergh ACM, Kerst JM, van den Belt-Dusebout AW, Lubberts S, Jóźwiak K, Horenblas S, van Leeuwen FE, Schaapveld M.

Br J Cancer. 2018 Oct;119(7):901-907. doi: 10.1038/s41416-018-0248-x. Epub 2018 Oct 9.

26.

Aortic allografts: final destination?-a summary of clinical tracheal substitutes.

Siddiqi S, de Wit R, van der Heide S, Oosterwijk E, Verhagen A.

J Thorac Dis. 2018 Aug;10(8):5149-5153. doi: 10.21037/jtd.2018.07.108. Review.

27.

Superior efficacy of neoadjuvant chemotherapy and radical cystectomy in cT3-4aN0M0 compared to cT2N0M0 bladder cancer.

Hermans TJN, Voskuilen CS, Deelen M, Mertens LS, Horenblas S, Meijer RP, Boormans JL, Aben KK, van der Heijden MS, Pos FJ, de Wit R, Beerepoot LV, Verhoeven RHA, van Rhijn BWG.

Int J Cancer. 2019 Mar 15;144(6):1453-1459. doi: 10.1002/ijc.31833. Epub 2018 Sep 24.

PMID:
30155893
28.

Risk of Solid Cancer After Treatment of Testicular Germ Cell Cancer in the Platinum Era.

Groot HJ, Lubberts S, de Wit R, Witjes JA, Kerst JM, de Jong IJ, Groenewegen G, van den Eertwegh AJM, Poortmans PM, Klümpen HJ, van den Berg HA, Smilde TJ, Vanneste BGL, Aarts MJ, Incrocci L, van den Bergh ACM, Jóźwiak K, van den Belt-Dusebout AW, Horenblas S, Gietema JA, van Leeuwen FE, Schaapveld M.

J Clin Oncol. 2018 Aug 20;36(24):2504-2513. doi: 10.1200/JCO.2017.77.4174. Epub 2018 Jul 10.

PMID:
29989856
29.

An open-label, multicenter, phase Ib study investigating the effect of apalutamide on ventricular repolarization in men with castration-resistant prostate cancer.

Belderbos BPSI, de Wit R, Chien C, Mitselos A, Hellemans P, Jiao J, Yu MK, Attard G, Bulat I, Edenfield WJ, Saad F.

Cancer Chemother Pharmacol. 2018 Sep;82(3):457-468. doi: 10.1007/s00280-018-3632-6. Epub 2018 Jul 5.

30.

Reply to C. Ren et al.

Heller G, McCormack R, Kheoh T, Molina A, Smith MR, Dreicer R, Saad F, de Wit R, Aftab DT, Hirmand M, Limon-Carrera A, Fizazi K, Fleisher M, de Bono JS, Scher HI.

J Clin Oncol. 2018 Aug 1;36(22):2354-2356. doi: 10.1200/JCO.2018.78.2672. Epub 2018 Jun 12. No abstract available.

PMID:
29894273
31.

The constitutive activity of the virally encoded chemokine receptor US28 accelerates glioblastoma growth.

Heukers R, Fan TS, de Wit RH, van Senten JR, De Groof TWM, Bebelman MP, Lagerweij T, Vieira J, de Munnik SM, Smits-de Vries L, van Offenbeek J, Rahbar A, van Hoorick D, Söderberg-Naucler C, Würdinger T, Leurs R, Siderius M, Vischer HF, Smit MJ.

Oncogene. 2018 Jul;37(30):4110-4121. doi: 10.1038/s41388-018-0255-7. Epub 2018 Apr 30.

32.

Health-Related Quality-of-Life Analysis From KEYNOTE-045: A Phase III Study of Pembrolizumab Versus Chemotherapy for Previously Treated Advanced Urothelial Cancer.

Vaughn DJ, Bellmunt J, Fradet Y, Lee JL, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK, Necchi A, Gerritsen W, Gurney H, Quinn DI, Culine S, Sternberg CN, Mai Y, Li H, Perini RF, Bajorin DF, de Wit R.

J Clin Oncol. 2018 Jun 1;36(16):1579-1587. doi: 10.1200/JCO.2017.76.9562. Epub 2018 Mar 28.

PMID:
29590008
33.

Cell-free DNA in Advanced Prostate Cancer: A Biomarker Revolution Under Way?

van Soest RJ, Tombal B, Lolkema MP, de Wit R.

Eur Urol. 2018 Sep;74(3):292-293. doi: 10.1016/j.eururo.2018.03.002. Epub 2018 Mar 19. No abstract available.

PMID:
29566958
34.

An In-Depth Evaluation of the Validity and Logistics Surrounding the Testing of AR-V7 mRNA Expression in Circulating Tumor Cells.

Sieuwerts AM, Mostert B, van der Vlugt-Daane M, Kraan J, Beaufort CM, Van M, Prager WJC, De Laere B, Beije N, Hamberg P, Westgeest HM, Tascilar M, Dirix LY, Onstenk W, de Wit R, Lolkema MP, Mathijssen RHJ, Martens JWM, Sleijfer S.

J Mol Diagn. 2018 May;20(3):316-325. doi: 10.1016/j.jmoldx.2018.01.008. Epub 2018 Feb 21.

35.

Controversies in the Management of Clinical Stage I Seminoma: Carboplatin a Decade in-Time to Start Backing Out.

van de Wetering RAW, Sleijfer S, Feldman DR, Funt SA, Bosl GJ, de Wit R.

J Clin Oncol. 2018 Mar 20;36(9):837-840. doi: 10.1200/JCO.2017.76.5610. Epub 2018 Feb 1. No abstract available.

36.

Prognostic factors in men with metastatic castration-resistant prostate cancer treated with cabazitaxel.

Belderbos BPS, de Wit R, Hoop EO, Nieuweboer A, Hamberg P, van Alphen RJ, Bergman A, van der Meer N, Bins S, Mathijssen RHJ, van Soest RJ.

Oncotarget. 2017 Nov 16;8(63):106468-106474. doi: 10.18632/oncotarget.22474. eCollection 2017 Dec 5.

37.

Testosterone Diminishes Cabazitaxel Efficacy and Intratumoral Accumulation in a Prostate Cancer Xenograft Model.

Mout L, de Wit R, Stuurman D, Verhoef E, Mathijssen R, de Ridder C, Lolkema M, van Weerden W.

EBioMedicine. 2018 Jan;27:182-186. doi: 10.1016/j.ebiom.2017.12.024. Epub 2017 Dec 20.

38.

Circulating Tumor Cell Number as a Response Measure of Prolonged Survival for Metastatic Castration-Resistant Prostate Cancer: A Comparison With Prostate-Specific Antigen Across Five Randomized Phase III Clinical Trials.

Heller G, McCormack R, Kheoh T, Molina A, Smith MR, Dreicer R, Saad F, de Wit R, Aftab DT, Hirmand M, Limon A, Fizazi K, Fleisher M, de Bono JS, Scher HI.

J Clin Oncol. 2018 Feb 20;36(6):572-580. doi: 10.1200/JCO.2017.75.2998. Epub 2017 Dec 22.

39.

Influence of Enzalutamide on Cabazitaxel Pharmacokinetics: a Drug-Drug Interaction Study in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients.

Belderbos BPS, Bins S, van Leeuwen RWF, Oomen-de Hoop E, van der Meer N, de Bruijn P, Hamberg P, Overkleeft ENM, van der Deure WM, Lolkema MP, de Wit R, Mathijssen RHJ.

Clin Cancer Res. 2018 Feb 1;24(3):541-546. doi: 10.1158/1078-0432.CCR-17-2336. Epub 2017 Nov 17.

41.

First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study.

Balar AV, Castellano D, O'Donnell PH, Grivas P, Vuky J, Powles T, Plimack ER, Hahn NM, de Wit R, Pang L, Savage MJ, Perini RF, Keefe SM, Bajorin D, Bellmunt J.

Lancet Oncol. 2017 Nov;18(11):1483-1492. doi: 10.1016/S1470-2045(17)30616-2. Epub 2017 Sep 26.

PMID:
28967485
42.

Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial.

Petrylak DP, de Wit R, Chi KN, Drakaki A, Sternberg CN, Nishiyama H, Castellano D, Hussain S, Fléchon A, Bamias A, Yu EY, van der Heijden MS, Matsubara N, Alekseev B, Necchi A, Géczi L, Ou YC, Coskun HS, Su WP, Hegemann M, Percent IJ, Lee JL, Tucci M, Semenov A, Laestadius F, Peer A, Tortora G, Safina S, Del Muro XG, Rodriguez-Vida A, Cicin I, Harputluoglu H, Widau RC, Liepa AM, Walgren RA, Hamid O, Zimmermann AH, Bell-McGuinn KM, Powles T; RANGE study investigators.

Lancet. 2017 Nov 18;390(10109):2266-2277. doi: 10.1016/S0140-6736(17)32365-6. Epub 2017 Sep 12.

PMID:
28916371
43.

CXCR4-Specific Nanobodies as Potential Therapeutics for WHIM syndrome.

de Wit RH, Heukers R, Brink HJ, Arsova A, Maussang D, Cutolo P, Strubbe B, Vischer HF, Bachelerie F, Smit MJ.

J Pharmacol Exp Ther. 2017 Oct;363(1):35-44. doi: 10.1124/jpet.117.242735. Epub 2017 Aug 2.

PMID:
28768817
44.

Differences in Trial and Real-world Populations in the Dutch Castration-resistant Prostate Cancer Registry.

Westgeest HM, Uyl-de Groot CA, van Moorselaar RJA, de Wit R, van den Bergh ACM, Coenen JLLM, Beerlage HP, Hendriks MP, Bos MMEM, van den Berg P, van de Wouw AJ, Spermon R, Boerma MO, Geenen MM, Tick LW, Polee MB, Bloemendal HJ, Cordia I, Peters FPJ, de Vos AI, van den Bosch J, van den Eertwegh AJM, Gerritsen WR.

Eur Urol Focus. 2018 Sep;4(5):694-701. doi: 10.1016/j.euf.2016.09.008. Epub 2016 Oct 13.

PMID:
28753794
45.

Systematic Review of Immune Checkpoint Inhibition in Urological Cancers.

Rijnders M, de Wit R, Boormans JL, Lolkema MPJ, van der Veldt AAM.

Eur Urol. 2017 Sep;72(3):411-423. doi: 10.1016/j.eururo.2017.06.012. Epub 2017 Jun 20. Review.

PMID:
28645491
46.

International evaluation of the psychometrics of health-related quality of life questionnaires for use among long-term survivors of testicular and prostate cancer.

van Leeuwen M, Kieffer JM, Efficace F, Fosså SD, Bolla M, Collette L, Colombel M, De Giorgi U, Holzner B, van de Poll-Franse LV, van Poppel H, White J, de Wit R, Osanto S, Aaronson NK; European Organisation for Research and Treatment of Cancer Quality of Life Group; Genito-Urinary Cancers Group and Radiation Oncology Group; and the NCRN Testis Clinical Studies Group.

Health Qual Life Outcomes. 2017 May 11;15(1):97. doi: 10.1186/s12955-017-0670-4.

47.

A randomized phase II/III study of cabazitaxel versus vinflunine in metastatic or locally advanced transitional cell carcinoma of the urothelium (SECAVIN).

Bellmunt J, Kerst JM, Vázquez F, Morales-Barrera R, Grande E, Medina A, González Graguera MB, Rubio G, Anido U, Fernández Calvo O, González-Billalabeitia E, Van den Eertwegh AJM, Pujol E, Perez-Gracia JL, González Larriba JL, Collado R, Los M, Maciá S, De Wit R; SOGUG and DUOS.

Ann Oncol. 2017 Jul 1;28(7):1517-1522. doi: 10.1093/annonc/mdx186.

48.

Spatial patterns in coastal lagoons related to the hydrodynamics of seawater intrusion.

Fiandrino A, Ouisse V, Dumas F, Lagarde F, Pete R, Malet N, Le Noc S, de Wit R.

Mar Pollut Bull. 2017 Jun 15;119(1):132-144. doi: 10.1016/j.marpolbul.2017.03.006. Epub 2017 Mar 25.

PMID:
28347496
49.

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma.

Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK, Necchi A, Gerritsen W, Gurney H, Quinn DI, Culine S, Sternberg CN, Mai Y, Poehlein CH, Perini RF, Bajorin DF; KEYNOTE-045 Investigators.

N Engl J Med. 2017 Mar 16;376(11):1015-1026. doi: 10.1056/NEJMoa1613683. Epub 2017 Feb 17.

50.

Application of circulating tumor DNA in prospective clinical oncology trials - standardization of preanalytical conditions.

van Dessel LF, Beije N, Helmijr JC, Vitale SR, Kraan J, Look MP, de Wit R, Sleijfer S, Jansen MP, Martens JW, Lolkema MP.

Mol Oncol. 2017 Mar;11(3):295-304. doi: 10.1002/1878-0261.12037. Epub 2017 Feb 22.

Supplemental Content

Loading ...
Support Center